PLCG1 - Phospholipase C Gamma 1
Introduction
flowchart TD
PLCG1["PLCG1"] -->|"biomarker for"| Tumor["Tumor"]
PLCG1["PLCG1"] -->|"activates"| oncogenic_pathway_activation["oncogenic pathway activation"]
PLCG1["PLCG1"] -->|"therapeutic target"| Glioblastoma["Glioblastoma"]
PLCG1["PLCG1"] -->|"therapeutic target"| Cancer["Cancer"]
PLCG1["PLCG1"] -->|"activates"| Tumor["Tumor"]
PLCG1["PLCG1"] -->|"therapeutic target"| Ms["Ms"]
PLCG1["PLCG1"] -->|"activates"| Senescence["Senescence"]
PLCG1["PLCG1"] -->|"activates"| LAMP2A["LAMP2A"]
PLCG1["PLCG1"] -->|"associated with"| TET2["TET2"]
PLCG1["PLCG1"] -->|"associated with"| TP53["TP53"]
PLCG1["PLCG1"] -->|"associated with"| U2AF1["U2AF1"]
PLCG1["PLCG1"] -->|"activates"| AUTOPHAGY["AUTOPHAGY"]
PLCG1["PLCG1"] -->|"co expressed with"| TET2["TET2"]
PLCG1["PLCG1"] -->|"co expressed with"| TP53["TP53"]
style PLCG1 fill:#4fc3f7,stroke:#333,color:#000
PLCG1 (Phospholipase C Gamma 1) encodes a key signaling enzyme that hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to generate diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). This phospholipase C isoform is uniquely activated by receptor tyrosine kinases (RTKs) via its tandem SH2 domains, making it a critical bridge between growth factor signaling and intracellular calcium mobilization. In the brain, PLCG1 participates in synaptic transmission, neuronal development, and neuroplasticity, while dysregulation contributes to neurodegenerative disease pathogenesis.
...PLCG1 - Phospholipase C Gamma 1
Introduction
Mermaid diagram (expand to render)
PLCG1 (Phospholipase C Gamma 1) encodes a key signaling enzyme that hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to generate diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). This phospholipase C isoform is uniquely activated by receptor tyrosine kinases (RTKs) via its tandem SH2 domains, making it a critical bridge between growth factor signaling and intracellular calcium mobilization. In the brain, PLCG1 participates in synaptic transmission, neuronal development, and neuroplasticity, while dysregulation contributes to neurodegenerative disease pathogenesis.
<div class="infobox infobox-gene">
<div class="infobox-header">Gene Information</div>
<div class="infobox-content">
Symbol: PLCG1
Full Name: Phospholipase C Gamma 1
Chromosomal Location: 20q12-q13.11
NCBI Gene ID: [5335](https://www.ncbi.nlm.nih.gov/gene/5335)
OMIM: [172420](https://www.omim.org/entry/172420)
Ensembl ID: ENSG00000124181
UniProt ID: [P19174](https://www.uniprot.org/uniprot/P19174)
Associated Diseases: Alzheimer's disease, Parkinson's disease, Schizophrenia, Cancer
</div>
</div>
Protein Structure and Function
Catalytic Domains
PLCG1 is a 1290-amino acid protein with a modular domain architecture[@gresset2010]:
- X domain: Phosphorylase C-like phosphodiesterase core that catalyzes PIP2 hydrolysis
- Y domain: Regulatory accessory domain required for catalytic activity
- C2 domain: Calcium-dependent membrane targeting
- SH2 domain (x2): Tandem Src homology 2 domains for RTK binding and phosphotyrosine recognition
- SH3 domain: Proline-rich region for cytoskeletal protein interactions
Activation Mechanism
PLCG1 activation involves multiple steps[@hardie1995]:
RTK autophosphorylation: Growth factor binding triggers RTK autophosphorylation on specific tyrosine residues
SH2 domain binding: The tandem SH2 domains of PLCg1 bind to phosphotyrosine motifs on activated RTKs or adapter proteins
Phosphorylation: PLCg1 is phosphorylated on multiple tyrosine residues (Tyr771, Tyr783, Tyr1254) by the RTK
Membrane recruitment: C2 domain and membrane PIP2 interactions bring PLCg1 to the plasma membrane
Catalytic activation: Phosphorylation and membrane localization activate the catalytic X domainSecond Messenger Generation
Activated PLCg1 produces two crucial second messengers[@berridge1993]:
- DAG: Remains in the membrane, activates protein kinase C (PKC) and related kinases
- IP3: Diffuses to the endoplasmic reticulum, triggering calcium release via IP3 receptors
Role in Neurodegeneration
Alzheimer's Disease
PLCG1 is heavily implicated in Alzheimer's disease pathogenesis through multiple mechanisms[@querfurth2010]:
- APP processing: PLCg1 influences amyloid precursor protein (APP) processing through PKC-dependent pathways. PKC activation promotes non-amyloidogenic alpha-secretase cleavage, while PLCg1 dysregulation shifts processing toward amyloidogenic beta- and gamma-secretase pathways[@cao2012].
- Calcium dysregulation: Aβ oligomers cause excessive PLCg1 activation, leading to IP3-mediated calcium release from ER stores. This calcium dysregulation contributes to excitotoxicity and neuronal death[@demuro2011].
- Synaptic dysfunction: PLCg1-mediated signaling is essential for synaptic plasticity. In AD, Aβ-induced PLCg1 hyperactivation disrupts long-term potentiation (LTP) and memory formation[@shankar2008].
- Tau pathology: PKC activation by DAG modulates GSK-3β activity, directly affecting tau phosphorylation. PLCg1 dysregulation thus contributes to neurofibrillary tangle formation[@gong2004].
Parkinson's Disease
In Parkinson's disease, PLCg1 participates in[@plattner2020]:
- Dopaminergic signaling: PLCg1 modulates dopamine receptor signaling in striatal medium spiny neurons. Dysregulation affects motor control and reward processing.
- α-Synuclein aggregation: Calcium dysregulation caused by PLCg1 hyperactivation promotes α-synuclein aggregation and toxicity[@calo2016].
- Mitochondrial dysfunction: PLCg1-mediated calcium signals influence mitochondrial health and can trigger apoptotic pathways in dopaminergic neurons.
Amyotrophic Lateral Sclerosis
PLCG1 variants and dysregulation have been linked to ALS[@ferraiuolo2011]:
- Motor neuron vulnerability: PLCg1 signaling affects excitability and survival of motor neurons
- Glial contributions: Astrocytic PLCg1 regulates glutamate uptake; dysregulation contributes to excitotoxicity
- TDP-43 pathology: PLCg1 interacts with RNA granules; its dysregulation may contribute to TDP-43 aggregation
Synaptic Function
Neurotransmitter Release
PLCG1 plays essential roles in synaptic transmission[@brose1992]:
- Presynaptic vesicle release: IP3-mediated calcium release modulates vesicle fusion and neurotransmitter release
- Synaptic plasticity: DAG-PKC signaling is crucial for LTP and long-term depression (LTD)
- Retrograde signaling: Endocannabinoid release involves PLCg1-dependent pathways
Receptor Signaling
PLCG1 integrates signals from multiple receptor types:
| Receptor | PLCg1 Role | Neurobiological Effect |
|----------|-----------|----------------------|
| TrkA/B | Direct activation | NGF/BDNF signaling |
| EGFR | Indirect activation | Growth factor responses |
| mGluR1/5 | Gq-coupled activation | Glutamate signaling |
| 5-HT2A | Gq-coupled activation | Serotonin modulation |
| D1/D5 | Gq-coupled activation | Dopamine modulation |
Therapeutic Implications
Targeting PLCg1
PLCG1 represents a therapeutic target for neurodegenerative diseases[@gurley1996]:
- PKC inhibitors: PKC modulators indirectly affect PLCg1 downstream signaling
- IP3 receptor antagonists: Drugs targeting IP3 receptors can prevent excessive calcium release
- Calcium stabilizers: Compounds that buffer intracellular calcium may counteract PLCg1 dysregulation
Small Molecule Inhibitors
Several PLC inhibitors have been developed:
- U73122: Classic PLC inhibitor, though limited by poor selectivity
- Edelfosine: Alkylphospholipid that inhibits PLCg1
- D609: Selective for PLCg1 over other PLC isoforms
Protein Interactions
Kinase Interactions
| Protein | Interaction Type | Functional Consequence |
|---------|-----------------|----------------------|
| PDGFR | Direct binding | Growth factor activation |
| EGFR | Direct binding | Growth factor activation |
| TrkA | Direct binding | NGF signaling |
| PKCα | DAG-dependent | Signal transduction |
| Src | Tyrosine phosphorylation | Activation regulation |
Scaffold Proteins
- LAT: Linker for activation of T cells, scaffolds PLCg1 in immune cells
- SLP-76: Cooperates with LAT in signaling complexes
- Grb2: Adapter protein that recruits PLCg1 to RTKs
Expression Patterns
Brain Regional Distribution
PLCG1 is widely expressed in the brain with highest levels in[@huntsman1999]:
- Hippocampus: Particularly CA1 and dentate gyrus, regions critical for memory
- Cerebral cortex: Layer-specific expression patterns
- Cerebellum: Purkinje cells show high expression
- Striatum: Medium spiny neurons express PLCg1
Cell Type Distribution
- Neurons: High expression in excitatory and inhibitory neurons
- Astrocytes: Moderate expression, participates in calcium signaling
- Microglia: Activation-dependent expression
- Oligodendrocytes: Myelination-associated expression
Signaling Pathways
Downstream Effects
PLCG1 activation triggers multiple signaling cascades[@watt2019]:
Growth Factor → RTK → PLCg1 → DAG + IP3
↓
┌──────┴──────┐
↓ ↓
PKC Activation Ca²⁺ Release
↓ ↓
┌──────┴──────┐ ↓
↓ ↓ ↓
MAPK/ERK Gene Expression Exocytosis
Activation (CREB) Synaptic Transmission
Cross-talk with Other Pathways
PLCG1 interacts with numerous signaling pathways:
- MAPK/ERK pathway: PKC activation leads to Raf/MEK/ERK activation
- PI3K/Akt pathway: Cross-talk regulates cell survival
- Calcium/calmodulin pathways: Calcium influx activates calcineurin and CaMKII
Genetic Associations
Neurodegenerative Disease Variants
| Disease | Variant | Effect | Reference |
|---------|---------|--------|----------|
| Alzheimer's disease | rs2293309 | Risk modification | GWAS |
| Parkinson's disease | rs1249768 | Altered expression | eQTL study |
| Schizophrenia | rs6011300 | Association | GWAS |
Research Directions
Biomarker Potential
PLCG1 activity in cerebrospinal fluid may serve as a biomarker for synaptic dysfunction in neurodegenerative diseases[@plcg2022]. Phosphorylated PLCg1 levels correlate with disease severity in some contexts.
Model Systems
- Knockout mice: Plcg1 knockout is embryonic lethal; conditional knockouts reveal neuronal functions
- iPSC models: Patient-derived neurons allow study of PLCg1 variants
- Organoid systems: Brain organoids reveal developmental roles
Disease Associations
Top DisGeNET gene-disease associations for this gene are listed below. Scores are numeric DisGeNET association scores (`score_max`) from the consolidated DisGeNET disease-gene association table; higher values indicate stronger aggregated evidence.
| Disease | DisGeNET score | Evidence sources | Supporting PMID count |
|---|---:|---|---:|
| sarcoma | 0.211 | BeFree/CTD_human | 2 |
| bipolar disorder | 0.005 | BeFree/GAD | 2 |
| hematologic cancer | 0.003 | BeFree/LHGDN | 2 |
| multiple sclerosis | 0.002 | GAD | 1 |
| prostate cancer | 0.001 | BeFree | 3 |
Source: DisGeNET-derived consolidated disease-gene associations (`dhimmel/disgenet`, gene symbol `PLCG1`).
See Also
- [Phospholipase C Signaling](/mechanisms/phospholipase-c-signaling)
- [Calcium Signaling in Neurodegeneration](/mechanisms/calcium-dysregulation-neurodegeneration)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Synaptic Plasticity](/mechanisms/synaptic-plasticity-neurodegeneration)
- [APP Processing](/mechanisms/app-processing-amyloid)
References
[Unknown, Rhee & Bae, The role of phospholipase C in cell signaling (1995) (1995)](https://pubmed.ncbi.nlm.nih.gov/7649274/)
[Wilde et al., Regulation of PLCγ isoforms in cellular signaling (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31142892/)
[Frost et al., Phospholipase C signaling in brain function and disease (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/26158855/)
[Gresset et al., Structure of PLCγ1 SH2-FG loop (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20084266/)
Unknown, Hardie & Hanks, The protein kinase factsbook (1995) (1995)
[Unknown, Berridge, Inositol trisphosphate and calcium signaling (1993) (1993)](https://pubmed.ncbi.nlm.nih.gov/8408218/)
[Unknown, Querfurth & Schecher, Calcium hypothesis of Alzheimer's disease (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20375062/)
[Cao et al., PLCγ1 and APP processing (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/22820455/)
[Demuro et al., Calcium dysregulation by Aβ oligomers (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/21183701/)
[Shankar et al., Synaptic dysfunction by Aβ oligomers (2008) (2008)](https://pubmed.ncbi.nlm.nih.gov/18669888/)
[Gong et al., PKC and tau phosphorylation (2004) (2004)](https://pubmed.ncbi.nlm.nih.gov/14985504/)
[Unknown, Plattner & Irvine, PLC signaling in Parkinson's disease (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32042265/)
[Calo et al., Calcium and α-synuclein aggregation (2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/27067641/)
[Ferraiuolo et al., PLC signaling in ALS (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/22031351/)
[Brose et al., Synaptic vesicle cycle (1992) (1992)](https://pubmed.ncbi.nlm.nih.gov/1351747/)
[Gurley et al., PLC as therapeutic target (1996) (1996)](https://pubmed.ncbi.nlm.nih.gov/8764355/)
[Huntsman et al., Regional distribution of PLC isoforms (1999) (1999)](https://pubmed.ncbi.nlm.nih.gov/10567247/)
[Unknown, Watt & Molleman, PLCγ1 downstream pathways (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31783353/)
[Unknown, PLCG1 as biomarker for neurodegeneration (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35298894/)Pathway Diagram
The following diagram shows the key molecular relationships involving PLCG1 - Phospholipase C Gamma 1 discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)